Shorter Radiation Schedule for the Treatment of Prostate Cancer

Inclusion Criteria: histologic diagnosis of adenocarcinoma of the prostate with no evidence of metastatic disease to the nodes, bone or lung stage T1a moderately or poorly differentiated, T1b, T1c or T2 by the current UICC-TNM classification Exclusion Criteria: PSA > 40 mcg/L previous therapy for carcinoma of the prostate other than biopsy or TURP, including patients previously on hormone therapy for treatment of their prostate cancer prior or active malignancy other than non-melanoma skin cancer; or colon or thyroid cancer treated a minimum of five years prior to study entry and presumed cured simulated volume exceeds 1000 cm3 previous pelvic radiotherapy inflammatory bowel disease serious non-malignant disease which would preclude radiotherapy or surgical biopsy geographic inaccessibility for follow-up psychiatric or addictive disorder which would preclude obtaining informed consent or adherence to protocol unable to commence radiation therapy within 26 weeks of the date of last prostatic biopsy failure to give informed consent to participate in the study